BidaskClub downgraded shares of Marinus Pharmaceuticals (NASDAQ:MRNS) from a buy rating to a hold rating in a research report released on Monday.
Several other brokerages also recently issued reports on MRNS. Zacks Investment Research raised shares of Marinus Pharmaceuticals from a sell rating to a hold rating in a report on Wednesday, October 10th. Cantor Fitzgerald set a $19.00 price target on shares of Marinus Pharmaceuticals and gave the company a buy rating in a report on Tuesday, September 25th. Mizuho reissued a buy rating and set a $13.00 price target on shares of Marinus Pharmaceuticals in a report on Thursday, August 2nd. Finally, ValuEngine downgraded shares of Marinus Pharmaceuticals from a buy rating to a hold rating in a report on Saturday, October 6th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of Buy and a consensus target price of $19.67.
Marinus Pharmaceuticals stock opened at $6.14 on Monday. The firm has a market capitalization of $405.25 million, a price-to-earnings ratio of -7.68 and a beta of 2.53. Marinus Pharmaceuticals has a 12 month low of $3.31 and a 12 month high of $10.54.
Institutional investors and hedge funds have recently made changes to their positions in the company. Trexquant Investment LP acquired a new position in shares of Marinus Pharmaceuticals during the second quarter valued at $102,000. GSA Capital Partners LLP bought a new stake in shares of Marinus Pharmaceuticals during the second quarter valued at about $141,000. Rhumbline Advisers bought a new stake in shares of Marinus Pharmaceuticals during the second quarter valued at about $245,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Marinus Pharmaceuticals during the second quarter valued at about $363,000. Finally, Alps Advisors Inc. bought a new stake in shares of Marinus Pharmaceuticals during the second quarter valued at about $416,000. 63.64% of the stock is owned by institutional investors.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid.
Featured Story: How does inflation affect different investments?
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.